Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators designed to help investors select stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Value Score focuses on identifying undervalued stocks using financial ratios like P/E, PEG, and Price/Sales [3] - The Growth Score assesses a company's financial health and future outlook through projected and historical earnings, sales, and cash flow [4] - The Momentum Score identifies optimal times to invest based on price trends and earnings estimate changes [5] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for evaluating stocks based on value, growth, and momentum [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to facilitate portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.93% since 1988, significantly outperforming the S&P 500 [7][8] - There are over 800 stocks rated 1 or 2, making it essential for investors to select stocks with high Style Scores to maximize potential success [9] Stock Analysis: Quest Diagnostics (DGX) - Quest Diagnostics Inc. provides diagnostic information services to a wide range of customers, including physicians and hospitals, and is a key provider of reference testing for about half of U.S. hospitals [11] - DGX holds a 3 (Hold) rating on the Zacks Rank, with a VGM Score of B, and is projected to have a year-over-year earnings growth of 9.6% for the current fiscal year [12] - The Zacks Consensus Estimate for DGX has increased by $0.05 to $9.79 per share, with eight analysts revising their earnings estimates upwards in the last 60 days [12] - With a solid Zacks Rank and strong Growth and VGM Style Scores, DGX is recommended for investors' consideration [13]

Financial Data and Key Metrics Changes - Exagen reported Q3 2025 revenue of $17.2 million, marking the highest quarter in the company's history and a nearly 40% increase compared to Q3 2024 [19] - Year-to-date revenue grew by 19% to approximately $50 million, with a trailing twelve-month average selling price (ASP) up over 9% and volume up over 8% [20][19] - Gross margin for Q3 was just over 58%, a decrease of about 175 basis points from the previous year, but year-to-date gross margin was just over 59%, up about 60 basis points [23][24] Business Line Data and Key Metrics Changes - The Pharma and CRO business generated nearly $800,000 in revenue for Q3, bringing the year-to-date total to $1.2 million, a significant increase from $100,000 in 2024 [15][20] - Testing volume for CTD was up 15% from Q3 of last year, contributing to overall revenue growth despite ASP challenges [19] Market Data and Key Metrics Changes - The company expanded its sales territories from 42 to 45, with total ordering physicians and orders per clinician continuing to trend upward [12][19] - The launch of new biomarkers, including anti PAD4 antibodies, is expected to enhance the company's market position, although initial revenue impact is anticipated to be modest [5][10] Company Strategy and Development Direction - Exagen aims to innovate in the biomarker space for rheumatoid arthritis, with a focus on personalized patient care and improved treatment outcomes [9][10] - The company is committed to profitable growth and plans to continue expanding sales territories where opportunities exist [12][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting strong volume growth and the potential for ASP improvements despite current challenges [19][26] - The company remains focused on achieving positive cash flow and disciplined capital allocation to support growth initiatives [17][25] Other Important Information - The company expects to deliver between $65 million to $70 million in revenue for the year, with the potential to be cash flow positive at the high end of the range [17] - Exagen's balance sheet remains strong, with $35.7 million in cash and cash equivalents at the end of Q3, up from $30 million at the end of Q2 [27][28] Q&A Session Summary Question: Update on revenue per territory for Q3 - The revenue per territory was slightly below the previous record of $430,000 due to the addition of new territories, but growth is expected over time [30][32] Question: Incremental uplift to ASP from new RA markers - The company is gathering payment history for the new RA markers and expects a modest uplift compared to previous launches [33][34] Question: Strength of Pharma partnership with urine platform - The first statement of work related to the urine platform has been completed, with ongoing discussions for future projects [35][36] Question: ASP target of $500 - Management believes the $500 ASP target is still realistic, but timing is uncertain due to recent challenges with a high ASP direct bill account [40][44] Question: Volume growth and seasonal factors - Volume was up in Q3 relative to Q2, and October showed strong performance, although a slight step down is expected in Q4 due to holidays [48][50] Question: Strength of Pharma business and future potential - The Pharma services revenue is expected to continue growing, with opportunities in new disease areas and a strong pipeline [54][57] Question: Sales force expansion and rep productivity - It generally takes six to nine months for new sales reps to reach maturity, with recent hires showing strong early performance [63][66] Question: Denials related to new biomarkers - Higher denial rates are primarily related to new markers, with ongoing efforts to improve revenue cycle management and appeals processes [68][70]

Q3 2025 Financial Performance - Revenue reached $1,105 million, with a reported growth of +13% and organic growth of +12%[1] - Operating profit was $355 million[1] - Diluted earnings per share (EPS) stood at $3.40, reflecting a reported growth of +21% and comparable growth of +15%[1] - CAG (Companion Animal Group) revenue was $1,013 million, showing a reported growth of +14% and organic growth of +12%[1] - Water revenue reached $54 million, with a reported growth of +8% and organic growth of +7%[1] - LPD (Livestock, Poultry and Dairy) revenue was $34 million, demonstrating a reported growth of +17% and organic growth of +14%[1] 2025 Outlook - Revenue is projected to be between $4,270 million and $4,300 million, with a reported growth of 9.6% - 10.3% and organic growth of 8.8% - 9.5%[6,7] - Operating margin is expected to be 31.6% - 31.8%, with a reported margin expansion of 260 bps - 280 bps and comparable margin expansion of 80 bps - 100 bps[6,7] - EPS is forecasted to be $12.81 - $13.01, representing a reported growth of 20% - 22% and comparable growth of 12% - 14%[6,7] U.S. Companion Animal Practice Growth - As of September 30, 2025, U S total visits include clinical and non-clinical visits, there were an estimated ~330 million U S total visits in 2024[8,10] - Q3 2025 year-over-year growth in clinical visit was 2.0%[9] - Q3 2025 year-over-year growth in practice revenue was 4.5%[9]

Core Insights - Myriad Genetics announced that treatment informed by the GeneSight test resulted in faster initial remission and response in patients with Major Depressive Disorder (MDD), with benefits persisting over six months [1][2][3] Group 1: Study Overview - The PRIME Care study is the largest pharmacogenomic randomized controlled trial in mental health, enrolling 1,944 U.S. Veterans with depression to assess the impact of GeneSight results on treatment outcomes [2][4] - The study found that patients whose clinicians had GeneSight results were significantly more likely to achieve remission over 24 weeks, with a 28% higher likelihood compared to the usual care group [5][6] Group 2: Post-Hoc Analysis Findings - The post-hoc analysis included 1,764 veterans and focused on the time to first remission and response, showing that GeneSight test results increased the rate of remission and response over time [3][6] - Patients who took the GeneSight test were 27% more likely to achieve remission and 21% more likely to experience a significant reduction in depressive symptoms [8] Group 3: GeneSight Test Information - The GeneSight Psychotropic test is a leading pharmacogenomic test for over 60 medications commonly prescribed for mental health conditions, aimed at reducing the trial-and-error process in medication prescribing [7][8] Group 4: Company Background - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, dedicated to advancing health and well-being through molecular tests that guide treatment decisions across various medical specialties [8][9]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 increased to $3.6 billion, representing a 9% growth compared to last year [7] - Adjusted EPS grew by 19% to $4.18, with strong pre-free cash flow of $281 million [7][16] - Adjusted operating income was $513 million, or 14.4% of revenue, compared to $441 million, or 13.4% last year [15][16] Business Segment Data and Key Metrics Changes - Diagnostics revenue increased by 8.5%, with organic growth of 6% and margin improvement of 110 basis points [7][17] - Biopharma Laboratory Services (BLS) revenue grew by 8.3%, with organic revenue up 5.3% [18] - Central laboratories experienced a strong growth of 10%, or 7% in constant currency [8][18] Market Data and Key Metrics Changes - The quarterly book-to-bill ratio was 0.9, with a trailing 12-month ratio of 1.09, indicating strong demand [8][20] - The backlog for BLS was $8.6 billion, with an expected conversion of approximately $2.7 billion into revenue over the next 12 months [20] Company Strategy and Development Direction - The company aims to be the partner of choice for health systems and regional laboratories, focusing on high-growth therapeutic areas [9] - Recent acquisitions include clinical laboratory assets from Empire City Laboratories and Laboratory Alliance of Central New York, expected to close in Q1 2026 [10] - The company is expanding in specialty areas such as oncology, women's health, neurology, and autoimmune diseases [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver sustainable growth and long-term value for shareholders [23] - The company anticipates a $100 million impact from PAMA in 2026, with ongoing efforts to mitigate this through efficiency improvements [44][47] - The outlook for 2025 includes revenue growth guidance of 7.4% to 8% and adjusted EPS guidance of $16.15 to $16.50 [22] Other Important Information - The company is investing in digital and AI capabilities to enhance operational efficiency [13][14] - The Launchpad Initiative is on track to offset typical increases in personnel costs [15] Q&A Session Summary Question: Inquiry about revenue guidance and currency impact - Management clarified that $13 million of the guidance impact was from foreign exchange, with the rest related to timing of acquisitions [26][27] Question: Organic price per mix growth - Management noted that organic price mix grew by 2.8%, primarily driven by an increase in tests per session and Invitae's performance [32][34] Question: Site consolidation in early development - Management explained that the decision was based on the timing of study starts and expected a slight increase in operating income from the restructuring [38][40] Question: Expectations around PAMA - Management indicated ongoing advocacy for legislative changes to mitigate the impact of PAMA, with a $100 million expected impact for 2026 [44][47] Question: Consumer-driven testing contributions - Management reported significant growth in consumer testing initiatives, with plans to continue expanding the test offerings [51][53] Question: Diagnostic segment margin expansion - Management highlighted a 110 basis point margin improvement in diagnostics, driven by organic demand and Invitae's integration [56][58] Question: 2025 guidance range - Management kept the guidance range wider for BLS due to uncertainties around divestitures and site consolidations [62] Question: Central lab strength and bookings - Management confirmed strong growth in central laboratories, with expectations for continued strength in the upcoming quarters [88][89]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 increased to $3.6 billion, representing a 9% growth compared to the previous year [5] - Adjusted EPS grew by 19% to $4.18, with strong pre-free cash flow of $281 million [5][16] - Adjusted operating income was $513 million, or 14.4% of revenue, compared to $441 million, or 13.4% last year [15][16] Business Segment Data and Key Metrics Changes - Diagnostics revenue increased by 8.5%, with organic growth of 6% and margin improvement of 110 basis points [5][17] - Biopharma Laboratory Services (BLS) revenue grew by 8.3%, with organic revenue up by 5.3% [19] - Central laboratories experienced a strong growth of 10%, or 7% in constant currency [6][19] Market Data and Key Metrics Changes - The quarterly book-to-bill ratio was 0.9, with a trailing 12-month ratio of 1.09, indicating strong demand [6][19] - The company is divesting or restructuring approximately $50 million of annual revenue in non-core areas due to lower than anticipated revenue in early development [6][19] Company Strategy and Development Direction - The company aims to be the partner of choice for health systems and regional laboratories, focusing on high-growth therapeutic areas and leveraging science and technology for growth [7][10] - Recent acquisitions include clinical laboratory assets from Empire City Laboratories and Laboratory Alliance of Central New York, enhancing the company's market presence [8][9] - The company is expanding in specialty areas such as oncology, women's health, neurology, and autoimmune diseases, with innovative testing capabilities introduced [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver sustainable growth and long-term value for shareholders, despite challenges in early development [23][82] - The company anticipates a $100 million impact from PAMA in 2026, with ongoing efforts to mitigate this through operational efficiencies and AI initiatives [43][63] Other Important Information - The adjusted tax rate for the quarter was 23.3%, with expectations for the full year to be around 23% [16] - The company ended the quarter with $598 million in cash and total debt of $5.6 billion, resulting in a debt leverage of 2.4 times [16] Q&A Session Summary Question: Inquiry about revenue guidance and currency impact - Management clarified that $13 million of the revenue guidance adjustment was due to foreign exchange, with the rest related to timing of acquisitions [26][27] Question: Organic price per mix growth - Management noted that organic price mix grew by 2.8%, driven by an increase in tests per session and the impact of Invitae [32][34] Question: Site consolidation in early development - Management explained that the decision was based on the timing of study starts and the need to streamline operations, expecting a slight increase in operating income from this action [37][38] Question: Expectations around PAMA - Management discussed ongoing advocacy for legislative changes to mitigate the impact of PAMA, with a $100 million expected impact on revenue and earnings for 2026 [43][44] Question: Consumer-driven testing efforts - Management highlighted strong growth in the consumer business, with new tests launched and a focus on meeting patient needs through various platforms [49][50] Question: Diagnostic segment margin expansion - Management indicated that the 110 basis point margin improvement was driven by organic demand and the integration of Invitae, with expectations for continued strength [52][54] Question: Revenue and EPS accretion from acquisitions - Management projected that acquisitions would contribute 1.5% to 2.5% growth in a given year, with a strong pipeline of opportunities [76]

Financial Performance - The company's total adjusted EBITDA for 3Q25 was $610.3 million[6], compared to $538.9 million in 3Q24[6] - For the nine months ended September 30, 2025, the adjusted net income attributable to Labcorp Holdings Inc was $1038.3 million, compared to $939.9 million for the same period in 2024[22] - The adjusted earnings per share for the three months ended September 30, 2025, was $4.18, compared to $3.50 for the same period in 2024[23] Revenue Analysis - Enterprise revenues, as reported, for 3Q25 were $3,564 million, an increase of 8.6% year-over-year[8] - Diagnostics Laboratories revenues, as reported, for 3Q25 were $2,770 million, an increase of 8.5% year-over-year[8] - Biopharma Laboratory Services revenues, as reported, for 3Q25 were $799 million, an increase of 8.3% year-over-year[8] - The company's revenue growth in Diagnostics Laboratories for 3Q25 was primarily driven by volume (4.7%) and price/mix (3.7%)[15] Outlook for 2025 - The company updated its 2025 revenue guidance for Labcorp Enterprise to a range of $13.97 billion to $14.05 billion, representing a growth of 7.4% to 8.0% versus 2024 results[18] - The company updated its 2025 adjusted EPS guidance to a range of $16.15 to $16.50, representing a growth of 10.8% to 13.2% versus 2024 results[18] Biopharma Laboratory Services - The trailing twelve-month net orders for Biopharma Laboratory Services ending September 30, 2025, were $3.34 billion, with a net book-to-bill ratio of 1.09x[17]

Core Insights - Labcorp raised its annual profit forecast and exceeded estimates in the third quarter due to strong demand for its diagnostic tests [1] Company Performance - The laboratory operator reported better-than-expected results for the third quarter, indicating robust performance in its diagnostic testing segment [1] Financial Outlook - Labcorp's adjustment of its annual profit forecast suggests confidence in continued demand and operational efficiency moving forward [1]

Core Viewpoint - Myriad Genetics, Inc. will hold its third quarter 2025 earnings conference call on November 3, 2025, at 4:30 pm ET, with earnings released after market close on the same day [1]. Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focusing on advancing health and well-being through molecular tests that assess disease risk and guide treatment decisions [3]. Conference Call Details - The conference call will provide a financial overview and business update regarding the company's performance for the third quarter of 2025 [1]. - A live webcast of the conference call will be available on Myriad's Investor Relations website, and an archived version will be accessible after the call [2].

Financial Data and Key Metrics Changes - Consolidated revenues for Q3 2025 were $2.82 billion, reflecting a 13.1% increase year-over-year, with organic revenue growth of 6.8% [13][16] - Adjusted operating income was $458 million, or 16.3% of revenues, compared to $385 million, or 15.5% of revenues in the prior year [15] - Reported EPS was $2.16, up from $1.99 a year ago, while adjusted EPS increased to $2.60 from $2.30 [16] - Cash from operations year-to-date reached $1.42 billion, a 63.1% increase compared to the prior year [16] Business Line Data and Key Metrics Changes - Revenue from diagnostic information services grew by 13.5%, driven by organic growth across physician, hospital, and consumer channels [13] - In the physician channel, revenue grew approximately 17%, with organic growth in the high single digits [7] - The hospital channel saw low single-digit revenue growth, primarily driven by COLAB Solutions [8] - The consumer channel experienced strong double-digit growth, particularly from the questhealth.com platform [9] Market Data and Key Metrics Changes - Total volume measured by requisitions increased by 12.5% year-over-year, with organic volume up 3.9% [14] - The company noted a benefit of approximately 50 basis points in volume due to disruptions from the previous year [14] Company Strategy and Development Direction - The company is focused on delivering solutions for core clinical customers and expanding into consumer life sciences and data analytics [6] - Recent acquisitions are emphasized as key growth drivers, particularly in hospital outreach and independent labs [6] - The company announced a joint venture with Corewell Health to establish a lab services partnership in Michigan [2][8] - Project Nova aims to modernize the order-to-cash process, with significant investments expected in 2025 [12][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the potential delay of PAMA legislation, which could mitigate a projected $100 million impact next year [26] - The company anticipates continued strong demand for clinical solutions and is raising its full-year 2025 guidance [19] - Management highlighted the importance of consumer health channels, which are expected to maintain momentum into the next year [32] Other Important Information - The company received FDA Breakthrough Device designation for its Haystack MRD test, reinforcing its cancer monitoring innovation [10] - The company is targeting 3% annual cost savings and productivity improvements through its Invigorate program [11] Q&A Session Summary Question: What are the expectations for utilization levels into year-end? - Management noted that utilization levels are expected to continue as seen in Q3, with strong growth in the consumer health business contributing to this trend [24] Question: What are the latest expectations regarding PAMA? - Management indicated that while the RESULTS Act has been proposed, a delay in PAMA is considered more likely than the act passing, with a potential $100 million impact next year [26] Question: How is the consumer health channel performing relative to expectations? - The consumer health channel is performing slightly above expectations, with strong growth in both direct and indirect channels [30] Question: Can you provide insights on the impact of Project Nova investments? - Management confirmed that there will be a ramp-up in Project Nova investments in Q4, but this is not expected to negatively impact 2026 [110] Question: What is the status of the Haystack MRD test integration? - The Haystack MRD test is fully integrated into the company, with ongoing studies and positive market response expected to enhance its presence [94][95]